The validity of the pretreated, unilaterally MPTP-treated monkey as a model of Parkinson's disease: A detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297

Behavioural Pharmacology

Volumn 10, Issue 2, 1999, Pages 163-173

  Andringa, G ^a,b   Vermeulen, R J ^a   Drukarch, B ^a   Renier, W O ^c   Stoof, J C ^a   Cools, A R ^b,c  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Animal model; D1 agonist; D2 agonist; Dyskinesia; MPTP; Parkinsonism; Primate; Quinpirole; SKF 81297

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; QUINPIROLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DYSKINESIA; DYSTONIA; ELECTROENCEPHALOGRAM; INTRAMUSCULAR DRUG ADMINISTRATION; LIMB MOVEMENT; LOCOMOTION; MALE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; RHESUS MONKEY;

EID: 0033027407     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199903000-00005     Document Type: Article

References (51)

1. Andringa G, Lubbers L, Drukarch B, Stoof JC, Cools AR, (1999). The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958. Behav Pharmacol 10:175-182.
2. Arai N, Isaj M, Miyata H, Fukuyama J, Mizuta H, Kuno S (1995). Differential effects of three dopamine receptors agonists in MPTP-treated monkeys. J Neural Transm 10:55-62.
3. Asin KE, Domino EF, Nikkel A, Shiosaki K (1997). The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models for Parkinson's disease. J Pharmacol Exp Ther 281(1):454-459.
4. Barbeau A (1969). L-DOPA therapy in Parkinson's disease: a critical review of nine years' experience. Can Med Assoc J 101(13):59-68.
5. Bedard PJ, Di Paolo T, Falardeau P, Boucher R (1986). Chronic treatment with L-DOPA but not bromocriptine induces dyskinesia in MPTP Parkinsonian monkeys; correlation with spiperone binding. Brain Res, 379(2):294-299.
6. Birkmayer W, Riederer P, Youdin MBH, Linauer W (1975). The potentiation of the anti-akinetic effect after L-DOPA treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 36:303-326.
7. Blanchet P, Bedard PJ, Britton DR, Kebabian JW (1993). Differential effects of selective D-1 and D-2 dopamine receptor agonists on L-DOPA induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 267:275-279.
8. Booij J, Andringa G, Rijks LJM, Vermeulen RJ, De Bruin C, Boer, GJ, Janssen, AGM, Van Royen EA (1997). [123I]FP-CIT binds to the dopamine transporter as assesed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys.Synapse 27:183-190.
9. Braun A, Fabrini G, Mouradian MM (1987). Selective dopamine receptor agonist treatment in Parkinson's disease. J Neural Transm 68:41-50.
10. Calne DB, Stern GM, Spiers AS, Laurence DR (1969). L-DOPA in idiopathic Parkinsonism. Lancet 2(628):973-976.
11. Carey RJ (1991). Chronic L-DOPA treatment in the unilateral 6OHDA rat: evidence for behavioural sensitisation and biochemical tolerance. Brain Res 568(1-2):205-214.
12. Carman LS, Gage FH, Shults CW (1991). Partial lesion of the substantia nigra: relation between extent of the lesion and rotational behavior. Brain Research 553:275-283.
13. Cools AR (1981). The physiological significance of the striatal system: new light on an old concept. In: Advances in Physiology Sciences 2. Szentagothai J, Hamori J, Palkovitz M (editors).New York: Pergamon. pp 227-230.
14. Cools AR, Scheenen W, Eilam D, Golani I (1989). Evidence that apomorphine and (+)-amphetamine produce different types of circling in rats. Behav Brain Res 34:111.
15. DeNinno MP, Schoenleber R, MacKenzic R, Britton DR, Asin KE, Briggs C et al. (1991). A 68930: a potent agonist selective for the dopamine D1 receptor. Eur J Pharmacol 199:209-219.
16. Domino EF (1997a). Selective full dopamine D1 like (SKF 82958) and D2 like (N 0923) agonist combination in the MPTP monkey model of hemiparkinsonism, Brain Res Bull 43(1):93-95.
17. Domino EF (1997b). Talipexole and pramipexole combinations with chloro APB (SKF 82958) in MPTP induced hemiparkinsonian monkeys. Eur J Pharmacol 325(2-3):137-144.
18. Domino EF, Sheng J (1993). Relative potency and efficacy of some agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther 265(3):1387-1391.
19. Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA (1990). L-deprenyl, a MAO-B inhibitor, as an adjunct to convential L-DOPA therapy in Parkinson's disease: experience in 200 patients. Adv Neurol 53:431-435.
20. Glick SD, Carlson JN, Baird JL, Maisonneuve IM, Bullock AE (1988). Basal and amphetamine induced asymmetries in striatal dopamine release and metabolism: bilateral in vivo microdialysis in normal rats. Brain Res 473:161-164. Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P, Marsden CD (1995a). Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology 117:275-286.
21. Glick SD, Carlson JN, Baird JL, Maisonneuve IM, Bullock AE (1988). Basal and amphetamine induced asymmetries in striatal dopamine release and metabolism: bilateral in vivo microdialysis in normal rats. Brain Res 473:161-164. Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P, Marsden CD (1995a). Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology 117:275-286.
22. Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD (1995b). The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology 117:287-297.
23. Goldstein M, Lieberman A, Lew JY, Asano T, Rosenfeld MR, Makman MH (1980). Interaction of pergolide with central dopaminergic receptors. Proc Nat Acad Sci 77:3725-3728.
24. Gomez-Mancilla B, Bedard PJ (1991). effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 259:409-413.
25. Gomez-Mancilla B, Bedard PJ (1992). Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp Neurol 117:185-188.
26. Goulet M, Grondin R, Blanchet PJ, Bedard PJ, Di Paolo (1996). Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile of continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys. Brain Res 719:129-137.
27. Guttman M, Fibiger HC, Jakubovic A, Calne DB (1990). Intracarotid 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine administration: Biochemical and behavioural observations in a primate model of hemiparkinsonism. J Neurochem 54:1329-1334.
28. Hudson JL, Fong CS, Boyson SJ, Hoffer J (1994). Conditioned apomorphine-induced turning in 6-OHDA-lesioned rats. Pharmacol Biochem Behav 49(1):147-154.
29. Johnson BJ, Peacock V, Schneider JS (1995). Dihydrexine, a full dopamine D1 receptor agonist, induces rotational asymmetry in hemiparkinsonian monkeys. Pharmacol Biochem Behav 51(4):617-622.
30. Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, Schoenleber R, Williams R (1990). A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 229:203-209.
31. LeWitt P, Oakes D, Cui L (1997). The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group. Mov Disord 12(2):183-189.
32. Löschmann PA, Smith LA, Lange KW, Jähnig P, Jenner P, Marsden CD (1992). Motor activity following the administration of selective D1 and D2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology 109:49-56.
33. Luquin MR, Laguna J, Obeso JA (1992). Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol 31:551-554.
34. Marsden CD, Parkes JD (1976). 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1:292-296.
35. Morelli M, Di Chiara G (1987). Agonist-induced homologous and heterologous sensitisation to D-1 and D-2-dependent contraversive turning. Eur J Pharmacol 141:101-107.
36. Mouradian MM, Chase T (1988). Central mechanisms and levodopa response fluctuations in Parkinson's disease. Clin Neuropharmacol 4:378.
37. Nomoto M, Jenner P, Marsden CD (1988). The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist quinpirole in the MPTP-treated marmoset. Neurosci Lett 93:275-280
38. Nutt JG (1990). Levodopa induced dyskinesia: review, observations and speculation. Neurology 40:340-345.
39. Ovadia A, Zhang Z, Gash DM (1995). Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol Aging 16(6):931-937.
40. Parker JD, Debono AG, Marsden CD (1976). Bromocriptine in parkinsonism: long-term treatment, dose response, and comparison with levodopa. J Neurol Neurosur Psychiatry 39:1101-1108.
41. Richards JB, Sabol KE, Freed CR (1990). Unilateral dopamine depletion causes bilateral deficits in conditioned rotation in rats. Pharmacol Biochem Behav 36(2):217-223.
42. Riederer P, Youdim BH (1987). MPTP induced dopaminergic neurotoxicity- a useful model in the study of Parkinson's disease? Neurochem Int 11:379-381.
43. Roos PAC, Vredevoogd CB, van der Velde EA (1989). Response fluctuations in Parkinson's disease. Neurology 40:1344-1346.
44. Rouillard C, Bedard PJ, Di Paolo T (1990). Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393. Eur J Pharmacol 185:209-215.
45. Schneider JS, McLaughin WW, Roeltgen DP (1992). Motor and nonmotor behavioural deficits in monkeys made hemiparkinsonian by intracarotid MPTP infusion. Neurology 42:1565-1572.
46. Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, et al. (1996). ABT-431: The diacetyl prodrug of A-86929, a potent and selective stimulates motor behaviour in MPTP-lesioned monkeys. Eur J Pharmacol 235:143-147.
47. Vermeulen RJ, Drukarch B, Sahadat MCR, Goosen C, Wolters EC, Stoof JC (1993).The selective D1 agonist SKF 81297 stimulates motor behaviour in MPTP-lesioned monkeys. Eur J Pharmacol 235:143-147.
48. Vermeulen RJ, Drukarch B, Sahadat MC, Goosen C, Wolters EC, Stoof JC (1994). The dopamine D1 agonist SKF 81297 and the D2 agonist quinpirole act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-lesioned Parkinsonian rhesus monkeys. Mov Disord 9(6):664-672.
49. Watts VJ, Lawler CP, Gilmore JH, Southerland SB, Nichols DE, Mailman RB (1993). Dopamine D1 receptors: efficacy of full (dihydrexine) and partial (SKF 38393) agonists in primates vs rodents. Eur J Pharmacol 242:165-172.
50. Wieser HG, Hajek M (1995). Frontal lobe epilepsy: compartmentalization, presurgical evaluation and operative results. In: Epilepsy and the Functional Anatomy of the Frontal Lobe. Jasper HH, Riggio S, Goldman-Rakic PS (editors). New York: Raven Press, pp. 297-313.
51. Wolters EC, Vermeulen RJ, Goosen C, Stoof JC (1991). The unilateral MPTP lesioned monkey as an animal model of Parkinson's disease. In: Methods in Neuroscience Lesion and Transplantation. Conn PM (editor). San Diego: Academic Press. pp 153-167.